Levemir FlexPen & NovoRapid FlexPen - Important Safety Information from Novo Nordisk following approval by the Irish Medicines Board

Notice type: Advisory

Date: 02/02/2009

 

Problem Or Issue:
Please find attached safety information communication from Novo Nordisk regarding the importance of highlighting the differences between these products to patients administering them as part of the treatment of diabetes.

Important Safety Information-Levemir FlexPen and NovoRapid FlexPen


« Back